At both delivery (92 ) and in cord blood (95 ) samples and the HAI GMT was higher in cord blood samples (413.4, 95 confidence interval [CI] 297.6?74.2) than in maternal samples at delivery (275.3, 95 CI 208.3?63.9). These data indicate that maternal antibodies are transferred to and can protect infants from influenza virus infection during the first months of life.Influenza Vaccination in PregnancyThe safety profile of AdimFlu-SH, particularly the frequency and the severity of local and systemic events, was consistent with that found in prior studies of seasonal flu vaccines [35]. In general, the local and systemic events were mild to moderate 15481974 in severity, and no deaths of adverse events of special interest such as the optic neuritis, cranial neuropathy, brachial neuropathy, and GuillainBarre syndrome (GBS) were reported in this study. The majority of study subjects (93.2 ) did not report any complications during delivery, and those complications that did occur were deemed to be not related to the vaccine. All subjects had a live birth and no birth defects were reported. These data indicate that AdimFlu-SH is safe and well tolerated for pregnant women and their newborns. This study has limitations that should be considered. There were a small number of subjects and we were unable to determine a correlation of antibody titers with time after vaccination. We did not enroll pregnant women at the first trimester of gestation; although influenza vaccination is recommended for pregnant women regardless of the trimester, patients have safety concerns with vaccination in the first trimester of pregnancy. Only healthy pregnant women were studied. The results cannot be applied to the pregnant women with co-morbidity. Lastly, we showed that antibody titers declined over time, consistent with previous reports [21,34]. However, we did not collect long-term follow-up data and cannot determine if antibody titers fell to zero or if the mothers and infants ITI007 site developed influenza infections.ConclusionThis prospective study examined the immunogenicity, safety, and transplacental transmission of antibodies in pregnant women in Asia vaccinated with AdimFlu-SH and the results showed that AdimFlu-SH vaccination induces a strong immune response and is safe for pregnant women. Our data also indicate that maternal antibodies are transferred to the infants.Supporting InformationChecklist S1 CONSORT Checklist.(DOC)AKT inhibitor 2 price protocol S1 Trial protocol.(PDF)Text S1 The approval of the study by the Research Ethics Committee A of the National Taiwan University Hospital. (PDF)AcknowledgmentsThe authors thank all the study participants and their families.Author ContributionsConceived and designed the experiments: CNL. Performed the experiments: ETW CHL MKS. Analyzed the data: SYL. Contributed reagents/ materials/analysis tools: ETW CHL MKS CNL. Wrote the paper: SYL.
Human umbilical cord blood stem cells (HUCBSC) are potentially a very important source of stem cells for tissue repair, as their use would circumvent the ethical issues involved with embryonic stem cells. Furthermore, HUCBSC have already been extensively used for treating many haematological related disorders, hence they are believed to be safe [1,2]. Whereas there are a number of reports suggesting the human umbilical cord blood (hUCB) can give raise to different lineages, the issue of their origin and of the existence of a truly pluripotent population with the hUCB has been a matter of debate. Recently, much work has.At both delivery (92 ) and in cord blood (95 ) samples and the HAI GMT was higher in cord blood samples (413.4, 95 confidence interval [CI] 297.6?74.2) than in maternal samples at delivery (275.3, 95 CI 208.3?63.9). These data indicate that maternal antibodies are transferred to and can protect infants from influenza virus infection during the first months of life.Influenza Vaccination in PregnancyThe safety profile of AdimFlu-SH, particularly the frequency and the severity of local and systemic events, was consistent with that found in prior studies of seasonal flu vaccines [35]. In general, the local and systemic events were mild to moderate 15481974 in severity, and no deaths of adverse events of special interest such as the optic neuritis, cranial neuropathy, brachial neuropathy, and GuillainBarre syndrome (GBS) were reported in this study. The majority of study subjects (93.2 ) did not report any complications during delivery, and those complications that did occur were deemed to be not related to the vaccine. All subjects had a live birth and no birth defects were reported. These data indicate that AdimFlu-SH is safe and well tolerated for pregnant women and their newborns. This study has limitations that should be considered. There were a small number of subjects and we were unable to determine a correlation of antibody titers with time after vaccination. We did not enroll pregnant women at the first trimester of gestation; although influenza vaccination is recommended for pregnant women regardless of the trimester, patients have safety concerns with vaccination in the first trimester of pregnancy. Only healthy pregnant women were studied. The results cannot be applied to the pregnant women with co-morbidity. Lastly, we showed that antibody titers declined over time, consistent with previous reports [21,34]. However, we did not collect long-term follow-up data and cannot determine if antibody titers fell to zero or if the mothers and infants developed influenza infections.ConclusionThis prospective study examined the immunogenicity, safety, and transplacental transmission of antibodies in pregnant women in Asia vaccinated with AdimFlu-SH and the results showed that AdimFlu-SH vaccination induces a strong immune response and is safe for pregnant women. Our data also indicate that maternal antibodies are transferred to the infants.Supporting InformationChecklist S1 CONSORT Checklist.(DOC)Protocol S1 Trial protocol.(PDF)Text S1 The approval of the study by the Research Ethics Committee A of the National Taiwan University Hospital. (PDF)AcknowledgmentsThe authors thank all the study participants and their families.Author ContributionsConceived and designed the experiments: CNL. Performed the experiments: ETW CHL MKS. Analyzed the data: SYL. Contributed reagents/ materials/analysis tools: ETW CHL MKS CNL. Wrote the paper: SYL.
Human umbilical cord blood stem cells (HUCBSC) are potentially a very important source of stem cells for tissue repair, as their use would circumvent the ethical issues involved with embryonic stem cells. Furthermore, HUCBSC have already been extensively used for treating many haematological related disorders, hence they are believed to be safe [1,2]. Whereas there are a number of reports suggesting the human umbilical cord blood (hUCB) can give raise to different lineages, the issue of their origin and of the existence of a truly pluripotent population with the hUCB has been a matter of debate. Recently, much work has.
